Moderators: Gregory P. Guyton, MD; Glenn Pfeffer, MD
Faculty: Bruce Sangeorzan, MD; James Brodsky, MD

• My Treatment Algorithm for Cavovarus – Bruce Sangeorzan, MD
• Charcot-Marie-Tooth Disease: Recurrent Cavovarus – Glenn Pfeffer, MD
• Peroneal Tendon Tears in Cavovarus Deformity – James Brodsky, MD
• Tendons: What to Transfer and When – Gregory P. Guyton, MD

• At the conclusion of this webinar, you will be able to:
• Understand the common algorithm for surgical management of cavovarus deformity
• Understand the underlying deforming force and associated pathologies
• Understand tendon transfer options and indicate when and where to transfer
• Consider various factors and strategies to avoid recurrent deformity after surgical reconstruction

Commercial Support
2023 webinars are provided free to AOFAS members and orthopaedic residents/fellows with funding from the Orthopaedic Foot & Ankle Foundation, supported by grants from: Stryker and Arthrex, Inc.

Accreditation

The American Orthopaedic Foot & Ankle Society (AOFAS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

Credit Designation Statement

The AOFAS designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

A need for this educational activity has been determined based on previous course evaluations and the AOFAS educational curriculum. The content of this course was based on current issues and topics provided by AOFAS membership and leadership. For more information on the AOFAS CME mission, visit aofas.org/education.

AOFAS requires all instructors, planners, and other individuals in a position to control or influence the content of an educational activity to disclose all relevant financial relationships or affiliations during the past 12 months with any commercial interest (any entity producing, marketing, re-selling, or distributing healthcare goods and services consumed by, or used on patients). All identified conflicts of interest must be resolved and the education content vetted by AOFAS for fair balance, scientific objectivity, and appropriateness. AOFAS also requires faculty to disclose when off-label/unapproved uses of a product are discussed in a CME activity. AOFAS attests that the persons responsible for the development of this educational activity did so independently and were not influenced by commercial supporters. All financial disclosures will be provided to meeting attendees in the final program materials.

The material presented in this continuing medical education activity has been made available by the American Orthopaedic Foot & Ankle Society (AOFAS) for educational purposes only. This material is not intended to represent the only, nor necessarily the best, methods or procedures appropriate for the medical situation discussed, but rather is intended to present an approach, view, statement, or opinion of the authors or presenters, which may be helpful or of interest to other practitioners. Methods, techniques, and procedures demonstrated and views and opinions expressed by speakers, presenters, and faculty are their own, and do not necessarily represent those of AOFAS, nor does presentation on the program represent or constitute endorsement or promotion by AOFAS. AOFAS expressly disclaims any warranties or guarantees, expressed or implied, and shall not be liable for damages of any kind in connection with the material, methods, information, techniques, opinions, or procedures expressed, presented, or demonstrated.

FDA Statement
Some drugs or medical devices demonstrated at this meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical devices he or she wishes to use in clinical practice. AOFAS policy provides that “off label” uses of a drug or medical device may be described in its CME activities so long as the “off label” use of the drug or medical device is also specifically disclosed (i.e., it must be disclosed that the FDA has not cleared the drug or device for the described purpose). Any drug or medical device is being used “off label” if the described use is not set forth on the products approval label.

Faculty/Planner Disclosure Declaration
As an Accreditation Council for Continuing Medical Education (ACCME) provider, AOFAS has the obligation to ensure the delivery of education that is balanced and free of commercial bias. To achieve this, it is the policy of the AOFAS that all CME-related board members, committee members (“planners”), faculty, and appropriate staff disclose in writing to the learners’ all financial relationships that you have had in the past 24 months with ineligible companies. An “ineligible company” are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In addition to faculty members, commentators from the floor are charged with verbally disclosing any interests immediately prior to speaking. All disclosures are provided in this final program distributed at the meeting to all program participants.

In accordance with AOFAS policy:
Faculty participation in this educational activity will be predicated upon timely submission and review of AOFAS disclosure. An individual who refuses to disclose all financial relationships will be disqualified from being a planning committee member, a teacher, or an author of CME, and cannot have control of, or responsibility for, the development, management, presentation, or evaluation of the CME activity. Non-compliance will result in a faculty member being stricken from the program.

An indication of the participant’s disclosure appears after his or her name as well as the ineligible company that provided the support. AOFAS does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in this activity. In addition to ensuring that presentations be free of bias, faculty members are required to ensure that all material presented and discussed will be based on best- available evidence.

Webinar Faculty Disclosures

James Brodsky, MD
Nothing to disclose

Gregory P. Guyton, MD
Arthrex: Royalties
Clinical Orthopedics and Related Research: Editorial/Governing board - Publications
Director, American Board of Orthopaedic Surgery: Board member/Committee Member
Exactech: Paid Consultant
Foot and Ankle International: Editorial/Governing board - Publications
Paragon28: Paid Consultant
Stryker: Royalties

Glenn B. Pfeffer, MD
Nothing to Disclose

Bruce Sangeorzan, MD, FOAO, FAAOS
Nothing to disclose

EDUCATION COMMITTEE DISCLOSURES (Planners)

Mohamed Abd-Ella
Nothing to disclose 

Mostafa Abousayed, MD, MSc
Nothing to disclose 

Jonathon Backus, MD
AOFAS: Board member/Committee Member 
Marrow Access Technologies: Stock or stock options 
Medline Unite: Paid Consultant; Royalties - Publisher)

M. Truitt Cooper, MD
GLW: Stock-privately held company 
In2Bones: Paid Consultant; Royalties 
Smith & Nephew: Grant/Research Support
Stryker: Educational Grant (Ongoing)

Canon Cornelius, MD
Nothing to disclose  

Cesar de Cesar Netto, MD, PhD 
AAOS: Board member/Committee Member  
AOFAS: Board member/Committee Member 
Artelon: Paid Consultant; Royalties  
CurveBeam: Paid Consultant; Stock or stock options 
Foot & Ankle International: Editorial/Governing board - Publications 
Foot and Ankle Clinics: Editorial/Governing board - Publications  
International WBCT Society: Board member/Committee Member  
Medartis: Paid Consultant; Royalties 
Paragon 28: Grant/Research Support; Paid Consultant; Royalties  
Stryker: Paid Consultant 
Tayco Brace: Stock-privately held company  
Zimmer-Biomet: Paid Consultant: Royalties

Daniel Farber, MD
JMEA: Stock-privately held company  
Treace Medical Concepts, Inc.: Paid Consultant

Lauren Geaney, MD
AOFAS: Board member/Committee Member 
CT Orthopedic Society: Board member/Committee Member 
FAI: Editorial/Governing board – Publications
Novastep: Paid Consultant 
Paragon 28: Paid Consultant; Royalties 
Smith & Nephew: Paid Consultant 
Vilex: Paid Consultant

Amgad Haleem Amin, MD, PhD 
AOFAS: Board member/Committee Member; Editorial/Governing board  
Stryker: Paid Consultant; Speakers Bureau  
Vilex Medical: Paid Consultant; Speakers Bureau 

Tracy Harig, RN
Nothing to disclose

Jeannie Huh, MD
Nothing to disclose

Kenneth Hunt, MD
JISAKOS: Editorial/Governing board - Publications 
Panther Orthopaedics: Stock-privately held company
Paragon 28: Editorial/Governing board – Publications; Paid Consultant

Kelly Hynes, MD
Acumed LLC: Paid Consultant 
American Orthopaedic Foot and Ankle Society: Board member/Committee Member 
Canadian Orthopaedic Foot and Ankle Society: Board member/Committee Member 
Endo Pharmaceuticals Inc: Paid Consultant 
Ortho Xcel: Paid Consultant 

Brandon King, MD
Heron Therapeutics: Paid Consultant

Kwang-Bok Lee, MD, PhD
Nothing to disclose

Ashlee MacDonald, MD
Nothing to disclose 

Elizabeth Martin, MD 
AAOS: Board member/Committee Member
AOFAS: Board member/Committee Member 
Johnson & Johnson: Stock or stock options
Novastep: Paid Consultant 
Paragon28: Paid Consultant; Stock-privately held company

Max Michalski, MD
Arthrex Inc.: Grant/Research Support
Extremity Medical: Paid Consultant; Royalties; Speakers' Bureau 

Irvin Oh, MD
Innomed: Royalties
Joseph O’Neil, MD
Nothing to disclose 

Cristian Ortiz, MD
Acumed: Paid Consultant
AO: Board member/Committee Member

Charles Saltzman, MD
Lima Corporate: Unpaid Consultant
Nextremity Solutions: Paid Consultant
Paragon28: Paid Consultant 
Saunders/Mosby-Elsevier: Royalties - Publisher 
Vilex, LLC: Paid Consultant 
Zimmer Biomet: Royalties - Publisher 

Glenn Shi, MD
Nothing to disclose 

Monika Volesky, MD
AOFAS: Board member/Committee Member 
Arthrex: Paid Consultant 

Richard Zell, MD
Nothing to disclose 

Jacob Zide, MD
Orthofix: Paid Consultant

All of the relevant financial relationships listed for these individuals have been mitigated.